ALDER BIOPHARMACEUTICALS INC
DelistedCIK 1423824fmd_1AX7DVMGV0NYKAJ57VT5HJ3X9FManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2012 to Jun 30, 2019, 27 periods
| Line item | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 |
|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | 0 | 2 | 0 |
| Cost of revenue | – | – | – | – | 0 | – | – |
| Gross profit | – | – | – | – | 0 | – | – |
| Research and development | 31 | 32 | 33 | 70 | 133 | 253 | 239 |
| Total operating expenses | 38 | 40 | 46 | 86 | 159 | 293 | 287 |
| Operating income | (18) | (21) | 9 | (86) | (158) | (291) | (287) |
| Interest expense | 0 | – | – | – | – | – | 17 |
| Interest and investment income | 0 | 0 | 0 | 1 | 2 | 2 | 9 |
| Other non-operating income (expense) | 0 | 0 | 0 | 1 | 2 | 3 | (10) |
| Income before taxes | (18) | (21) | 9 | (85) | (156) | (289) | (296) |
| Net income | (18) | (21) | 9 | (85) | (156) | (289) | (296) |
| Net income to common shareholders | – | – | – | – | (156) | (289) | (332) |